-
Electronic (PDF)
-
Site License
-
Enterprisewide
Oncology Market in India to 2017 - Limited Patient Affordability for High Priced Biologics Lowers Market Potential
GBI Research, December 2010, Pages: 126
Oncology Market in India to 2017 - Limited Patient Affordability for High Priced Biologics Lowers Market Potential
Summary
GBI Research, the leading business intelligence provider, has released its latest research, “Oncology Market in India to 2017 – Limited Patient Affordability for High Priced Biologics Lowers Market Potential”, which provides insights into oncology sales and price forecasts until 2017. The report also examines the Indian oncology treatment usage patterns. In addition, the report also includes insights into the oncology R&D pipeline. The report provides an in-depth analysis of the top five oncology therapeutic indications, which are breast cancer, colorectal cancer, prostate cancer, lung cancer and Non-Hodgkin’s Lymphoma (NHL).
Scope
The report covers:
- Data and analysis on the oncology market in India.
- Annualized market data for the oncology market from 2002 to 2009, with forecasts to 2017.
- Market data on the therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population and treated population.
- Key drivers and restraints that have had a significant impact on the market and on each indication.
- The competitive landscape of the oncology market includes both Indian players and foreign players.
- Key M&A activities and Licensing Agreements that took place from 2004 to 2010 in the Indian oncology market.
Reasons to buy
The report will assist business development and marketing executives to strategize their product launches, by allowing them to:
- Build effective strategies to launch their pipeline products by identifying potential of the market.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Develop market-entry and market expansion strategies by identifying each indication’s growth rate.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.
1 3
1.1 List of Tables 6
1.2 List of Figures 8
2 Oncology Market in India: Introduction 10
2.1 GBI Research Report Guidance 11
3 Oncology Market in India: Market Characterization 12
3.1 Market Size 12
3.2 Annual Cost of Treatment 13
3.3 Treatment Usage Pattern 14
3.3.1 Diseased Population 15
3.3.2 Treated Population 16
3.4 Drivers 17
3.4.1 High Spending By Big Pharmaceutical Companies for Drug Trials 17
3.4.2 Larger Population Base 17
3.4.3 High Government Support and Initiatives 18
3.5 Barriers 19
3.5.1 Counterfeit Medical Products 19
3.5.2 Unfavorable Patent Law for Bigger Companies 19
3.5.3 Restrictive Pricing and Reimbursement Policies Causing Serious Problems in the Cancer Market Growth 19
3.5.4 Poor Infrastructure and Insufficient Trained Manpower 20
3.5.5 More than 80 Molecules to be launched Over the Next Seven Years, Leading to More Competition 20
3.6 Case Studies 21
3.6.1 Unfavorable Patent Law for Bigger Foreign Companies, Roche versus Cipla 21
3.6.2 Unfavorable Patent Law for Bigger Foreign Companies, Novartis – Glivec 23
4 Oncology Market in India: Therapeutic Landscape 25
4.1 Introduction 25
4.2 Breast Cancer 25
4.2.1 Market Size 25
4.2.2 Average Annual Cost of Treatment 26
4.2.3 Treatment Usage Pattern 27
4.2.4 Drivers 29
4.2.5 Restraints 30
4.3 Colorectal Cancer 31
4.3.1 Market Size 31
4.3.2 Annual Cost of Treatment 32
4.3.3 Treatment Usage Pattern 33
4.3.4 Drivers 35
4.3.5 Restraints 36
4.4 Prostate Cancer 37
4.4.1 Market Size 37
4.4.2 Annual Cost of Treatment 38
4.4.3 Drivers 39
4.4.4 Restraints 39
4.4.5 Treatment Usage Pattern 39
4.5 Lung Cancer 42
4.5.1 Market Size 42
4.5.2 Annual Cost of Treatment 43
4.5.3 Drivers 44
4.5.4 Restraints 44
4.5.5 Treatment Usage Pattern 45
4.6 Non-Hodgkin’s Lymphoma 48
4.6.1 Market Size 48
4.6.2 Annual Cost of Treatment 49
4.6.3 Drivers 50
4.6.4 Restraints 50
4.6.5 Treatment Usage Pattern 51
5 Oncology in India: Regulatory Landscape 54
5.1 Major Regulatory Bodies in India 54
5.1.1 The Central Drugs Standard Control Organization (CDSCO) 54
5.1.2 State Drug Regulatory Authority (SDRA) 55
5.2 IPR Protection in India 56
5.2.1 Effect of Patent Laws on Pharmaceutical Production in India 58
5.2.2 Key Impact of Newer Patent Laws on India 58
5.3 Key Regulations for Conducting Oncology Research in India 59
5.4 Government Initiatives to Support Oncology Research in India 60
5.4.1 Focus Areas 61
5.5 Oncology in India: Pricing and Reimbursements 62
5.5.1 Pricing of Oncology Drugs in India 62
5.5.2 Reimbursement of Oncology Drugs in India 65
6 Oncology in India: Pipeline Analysis 67
6.1 Key Area Focus for R&D in India 67
6.2 Pipeline Segmentation by Clinical Phase of Development 67
6.3 Pipeline Segmentation by Indication 68
6.3.1 Lung Cancer 69
6.3.2 Breast Cancer 70
6.3.3 Colorectal Cancer 71
6.3.4 Non-Hodgkin’s Lymphoma 72
6.3.5 Prostate Cancer 73
6.4 Key Late Stage Pipeline Drugs 74
6.4.1 Lung Cancer 74
6.4.2 Breast Cancer 75
6.4.3 Colorectal Cancer 77
6.4.4 Non-Hodgkin’s Lymphoma 81
6.4.5 Prostate Cancer 84
7 Oncology in India: Competitive Landscape 88
7.1 Key Indian Players in the Indian Oncology Market 88
7.1.1 Dr. Reddy’s Lab 88
7.1.2 Piramal Healthcare 91
7.1.3 Biocon Limited 95
7.1.4 Cipla Ltd. 97
7.2 Key Foreign Players in the Indian Oncology Market 100
7.2.1 Sanofi-Aventis 100
7.2.2 F. Hoffmann-La Roche Ltd/Genentech, Inc. 104
7.2.3 AstraZeneca 107
7.2.4 GlaxoSmithKline 109
8 Deals Landscape 112
8.1 Mergers and Acquisitions 112
8.1.1 Deals by Year 112
8.1.2 Deals by Type 113
8.1.3 Deal by Value 114
8.1.4 Top 10 M&A Deals 115
8.2 Licensing Agreements 118
8.2.1 Deals by Year 118
8.2.2 Deals by Value 119
8.2.3 Key Takeaway 120
8.2.4 Top 10 Licensing Deals 120
9 Appendix 123
9.1 Market Definitions 123
9.2 Abbreviations 123
9.3 Research Methodology 124
9.3.1 Coverage 124
9.3.2 Secondary Research 124
9.3.3 Primary Research 125
9.3.4 Expert Panel Validation 125
9.4 Contact Us 125
9.5 Disclaimer 125
9.6 Sources 126
“Oncology Market in India to 2017 - Limited Patient Affordability for High Priced Biologics Lowers Market Potential” provides insights into oncology sales and price forecasts until 2017. The report also examines the Indian oncology treatment usage patterns. In addition, the report also includes insights into the oncology R&D pipeline. The report provides an in-depth analysis of the top five oncology therapeutic indications, which are breast cancer, colorectal cancer, prostate cancer, lung cancer and Non-Hodgkin’s Lymphoma (NHL).
High Growth Rate and Increasing use of Biologics has made the Oncology Market Attractive
The overall market for five indications - breast cancer, colorectal cancer, prostate cancer, lung cancer and Non-Hodgkin’s Lymphoma (NHL) - was at $153.4m in 2009. This is expected to grow at a CAGR of 11.3% for the next eight years and will reach $361.9m.
High Support by Government and Increasing Incidence Rate among Large Population Base are not Big Enough Drivers for High Market Growth
The major drivers are large population base and increasing incidence rate, along with government support. However, the number of restraints is much higher than the drivers. Major restraints are pricing and patent issues. This has created a lot of issues in the past. Tarceva and Glivec are two famous cases which are still pending in court.
Along with these factors, reimbursement is also a major restraint. There are very few health policies which cover cancer diseases. Companies which provide such coverage either charge very high premiums or their conditions are very restrictive. Thus the Indian population is not able to fully utilize the benefits of newly developed drugs.
Strong Pipeline and the Entry of New Players Will Intensify the Competition
The global oncology market has a strong pipeline base that will support the growth of this market, thereby attracting many pharmaceutical and biotechnological companies. Major molecules are in Phase II and Phase III, so a high chance of intense competition can be predicted.
Major pharmaceutical companies such as Pfizer, Astrazeneca, Sanofi-Aventis, Merck, Roche and Novartis are active in their pipeline for oncology. The rapid entry of new players and the highly active pipeline will intensify competition.
Dr. Reddy’s Lab
Piramal Healthcare
Biocon Limited
Cipla Ltd.
Sanofi-Aventis
F. Hoffmann-La Roche Ltd/Genentech, Inc.
AstraZeneca
GlaxoSmithKline
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW6
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
